Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

ARDD 2026 brings global pharma, FDA leaders and longevity science pioneers to Harvard ...

18 September 2026 · By · Wire by Fusion42

Published

18 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at eurekalert.org →

◆ Verified

Fusion42 · 18 September 2026 · Fusion42 review

ARDD 2026 convenes global pharmaceutical leaders, FDA officials, investors, and researchers to discuss advancements in longevity biotechnology, regulatory pathways, AI drug discovery, and clinical trials at Harvard from October 1-3, 2026.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You must connect with pharma and regulatory leaders accelerating longevity drug trials now. The growing presence of AI and FDA voices signals fresh routes for clinical testing and commercialisation.

◆ Coverage

1 source · 18 Sep 2026

◆ Related on Wire

◆ Topics

Biotechpharma-executivesfda-regulationai-drug-discoveryclinical-trialslongevity-biolgyinvestment